Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D1.74 - Molecular IgE sensitization profiling in a patient with Asteraceae weed pollen allergy and anaphylaxis to honey
D1.75 - Anaphylaxis during Picc Line replacement
D1.76 - The Hot Chocolate Drink Dilemma
D1.77 - Perioperative Hypersensitivity Outcomes: A retrospective review of 112 patients seen between 2019 and 2024 at two allergy centres
D1.78 - Analytical Verification of Omega-5 gliadin (Tri a 19) Allergen Assay on the IMMULITE 2000 XPi System*
D1.79 - Cardiovascular symptoms during anaphylaxis: An analysis from the European Anaphylaxis Registry
D1.82 - Diagnostic challenges in amoxicillin-clavulanate anaphylaxis: an inconclusive in vitro study – Case Report
D1.83 - Asthma and multi-food allergy were risk factors for Oral Food Challenge failure
D1.84 - IgE-mediated allergy to chlorhexidine: case report
D1.85 - Basophil activation test in β-Lactam Anaphylaxis: A Case Series from a Tertiary Hospital
D1.86 - Hypersensitivity Reaction to Lugol’s Solution: A Case Report
D1.326 - Six Cases of Adult-Onset PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Cervical Adenopathy) Syndrome
D1.327 - A Rare Primary Immunodeficency Hidden in Autoimmunity: Heterozygote CD3G variant in a 49-year-old Female Patient
D1.332 - Hereditary Angioedema in Ukraine
D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach
D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia
D1.335 - TeloNet is born; why immunologists should know about telomere disorders
D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)
D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024
Download the app
The congress at your fingertips
Available on
Download